Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sequential Epirubicin and Docetaxel + Capecitabine in Locally Advanced Breast Cancer
NCT00645866Phase 2Completed
- Sponsor
- Mayo Clinic
- Start
- Apr 2003
- Primary completion
- Mar 2006
- Modality
- DNA Intercalators/Alkylators, Irreversible Covalent Inhibitors, RNA-Targeting Small Molecules
01
Overview
A Phase 2 trial of epirubicin, docetaxel, capecitabine in breast cancer, sponsored by Mayo Clinic. Started Apr 2003; status: completed.
02
Drugs
epirubicindocetaxelcapecitabine
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT00645866.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00645866.